ACE-86225106 / Acerand Therap - LARVOL DELTA

The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: Preliminary results from a first-in-human phase 1/2 study. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06380660 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1/2 data • Oncology • Solid Tumor

The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-in-human phase 1/2 study (EORTC-NCI-AACR 2024) - P1/2 | "Preliminary data indicate that ACE-86225106 is well tolerated and shows promising efficacy in heavily pre-treated advanced solid tumors."

Clinical • Metastases • P1/2 data • Bladder Cancer • Fallopian Tube Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma • BRCA • MUC16 • PARP2

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=298 | Recruiting | Sponsor: Acerand Therapeutics (Shanghai) Limited

Metastases • Monotherapy • New P1/2 trial • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor

Discovery of a highly potent and selective PARP1 inhibitor with superior PK and safety profiles (AACR 2024) - "Taken together, ACE-86225106 is a highly potent, selective PARP1 inhibitor with excellent PK and safety profile and expected to have a better safety profile, deeper and more durable clinical responses, and broader utility in the clinic as a preferred combination partner with other anti-cancer therapies. A phase 1 clinical trial to evaluate its safety, PK, and clinical utility is to begin in early 2024."

Clinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRCA • CD34 • HRD • PARP2